AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05268614
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will receive 40 mg/m2 of cisplatin intravenously over 60 minutes weekly during radiation therapy.~If cisplatin is not recommended by the treating medical oncologist or is not tolerated, it is permissible to switch to an alternative chemotherapy regimen per institutional practice, but chemotherapy should not be discontinued unless mandated by the patient's condition.
Trial: NCT05698147
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Selinexor dose escalation: 60,80,100mg respectively on day 1,8,15,22 for 28 days cycles, and dose expansion at the RP2D of Selinexor.~PR patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death.
Trial: NCT05698147
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
Trial: NCT00002259
Drug: Mitoxantrone hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05673824
Drug: VEGFR-TKIs
RxNorm normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment period: Therapeutic agents were selected according to clinical routine, including but not limited to Sorafenib, Lenvatinib, Donafenib, Regorafenib, Apatinib and Cabozantinib. Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
Trial: NCT06069180
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conditioning regimens were Bu/Flu/Cy/ATG or Bu/Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
Trial: NCT05973370
Drug: Ursodeoxycholic acid (UDCA) 500 mg
RxNorm normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an addon treatment to the current DMARDs treatments for rheumatoid arthritis.
Trial: NCT00002186
Drug: Crofelemer
RxNorm normalized name: Crofelemer
DrugBank: Crofelemer (DB04941)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002186
Drug: Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05130684
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: adding nivolumab to conventional neoadjuvant CRT
Trial: NCT06032858
Drug: Apremilast 30mg
RxNorm normalized name: APREMILAST 30MG TAB
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apremilast 30mg twice daily
Trial: NCT06107543
Drug: Nebulized Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before induction of anesthesia, 2% lidocaine + physiological saline was added to a nebulizer and inhaled for 3-5 minutes in the presence of 4-6 liters/minute of oxygen.
Trial: NCT06107543
Drug: Iv Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous %2 lidocaine was administered before induction of anesthesia.
Trial: NCT05800587
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care chemotherapy regimen
Trial: NCT05800587
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Standard of care chemotherapy regimen
Trial: NCT05800587
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard of care chemotherapy regimen
Trial: NCT05800587
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard of care chemotherapy regimen
Trial: NCT05800587
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care chemotherapy regimen
Trial: NCT05800587
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care chemotherapy regimen
Trial: NCT05800587
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care chemotherapy regimen
Trial: NCT05800587
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care chemotherapy regimen
Trial: NCT05800587
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care chemotherapy regimen
Trial: NCT05800587
Drug: Lurbinectedin
RxNorm normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care chemotherapy regimen
Trial: NCT04867083
Drug: ARV bitherapie
RxNorm normalized name: Arv-110 (protac)
DrugBank: Bavdegalutamide (DB19032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Dolutégravir 50mg / Lamivudine 300mg per day~2. Dolutégravir 50mg / Rilpivirine 25mg per day~3. Darunavir/r 800mg/100mg / Lamivudine 300mg per day
Trial: NCT06011317
Drug: EDG-7500
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDG-7500 is administered orally once daily
Trial: NCT04965298
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30mg (as 2 x 15mg capsules) twice daily, 12 hours apart, for 12 months. IMP should be taken at least 30 minutes before food.
Trial: NCT05718895
Drug: ATG-022
RxNorm normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation Phase:~A treatment cycle of ATG-022 will be defined as 21 days. Dosing will begin at 0.3 mg/kg once every 3 weeks (Q3W) with 1 subject ,the following dose cohorts (0.9, 1.8, 2.4, 3.0, and 3.6 mg/kg Q3W) will require at least 3 and up to 6 evaluable subjects by using dose escalation plan of 3+3 design.
Trial: NCT05930847
Drug: Use of medication for asthma
RxNorm normalized name: salicylic acid Medicated Patch [Compound W brand of salicylic acid]
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The children continued to take their current asthma medication on the same schedule. The drugs used by the children were zespira and ventolin.
Trial: NCT04896320
Drug: Tucatinib
RxNorm normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tucatinib is a highly selective, oral, reversibly Her2 small molecule tyrosine kinase inhibitor (TKI).
Trial: NCT05231850
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All eligible patients receive received 200 mg Tislelizumab intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
Trial: NCT04877769
Drug: AT-527
RxNorm normalized name: AT-527
DrugBank: AT-527 (DB16451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered twice daily (BID) for 2.5 days (5 doses in total)
Trial: NCT05735756
Drug: Citalopram 20mg
RxNorm normalized name: Escitalopram 20mg Oral tablet
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram 20mg once a day for 12 weeks
Trial: NCT05864508
Drug: Oxytocin nasal spray
RxNorm normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasal oxytocin treatment once a day during 6 weeks
Trial: NCT06271252
Drug: OriCAR-017
RxNorm normalized name: OriCar-017
DrugBank: OriCar-017 (DB17280)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-GPRC5D CAR-T cell product
Trial: NCT05045716
Drug: Lecanemab
RxNorm normalized name: Lecanemab
DrugBank: Lecanemab (DB14580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecanemab IV infusion.
Trial: NCT05045716
Drug: Lecanemab
RxNorm normalized name: Lecanemab
DrugBank: Lecanemab (DB14580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecanemab SC injection.
Trial: NCT04518254
Drug: L-Tyrosine 500 Mg
RxNorm normalized name: L-Tyrosine 500 mg
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route
Trial: NCT05749042
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Chemoradiotherapy Based of Cisplatin Plus Sintilimab.
Trial: NCT04848480
Drug: insulin icodec
RxNorm normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: insulin icodec 700 units/mL, subcutaneously (under the skin), solution for injection once weekly
Trial: NCT04848480
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: insulin degludec 100 units/mL, subcutaneously (under the skin), solution for injection once daily
Trial: NCT04848480
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: insulin aspart 100 units/mL, subcutaneously (under the skin), solution for injection daily
Trial: NCT05305898
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients from metformin group will receive metformin 3 x 850 mg (after titration period) for 2 years (3 x 500 mg for first 6 weeks) with 6 months follow-up after treatment cessation.
Trial: NCT05128071
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Randomized to 400 mg (200 mg twice daily) oral micronized progesterone daily
Trial: NCT06329635
Drug: Intrathecal Nicardipine
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First, 6 ml of cerebrospinal fluid is withdrawn from the EVD or LD catheter, and then 4 ml (4mg) of nicardipine is injected into the EVD or LD drain tube, followed by 2 ml normal saline solution, and then the EVD or LD tube is clamped for 2 hours, and then kept open as clinically necessary until the next dose (q12h) of medication.
Trial: NCT05077592
Drug: 10% Povidone Iodine
RxNorm normalized name: POVIDONE-IODINE 10 mg in 1 mL TOPICAL SOLUTION [10% Povidone Iodine Nasal Swab]
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine is a topical antiseptic agent used for the treatment and prevention of infection in wounds.
Trial: NCT04878107
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd
Trial: NCT04878107
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib \[Aitan® (brand name in China)\], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor
Trial: NCT04878107
Drug: Docetaxel injection
RxNorm normalized name: docetaxel Injection
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug
Trial: NCT05056558
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continued standard of care (SOC) together with oral 4 mg Baricitinib tablet from day 1 to day 14
Trial: NCT05074823
Drug: Ketamine 0.1 mg
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.1 mg/kg
Trial: NCT05074823
Drug: Ketamine 0.2 mg
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.2 mg/kg
Trial: NCT05074823
Drug: Ketamine 0.3 mg
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.3 mg/kg
Trial: NCT00000792
Drug: Hypericin
RxNorm normalized name: Hypericin
DrugBank: Hypericin (DB13014)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04652479
Drug: Avexitide
RxNorm normalized name: Avexitide
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor
Trial: NCT04703192
Drug: Valemetostat Tosylate
RxNorm normalized name: tazemetostat
DrugBank: Valemetostat (DB18314)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity
Trial: NCT03787628
Drug: Cannabidiol (CBD) 600 mg
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CBD (300 mg) will be administered orally twice daily in the morning and again in the afternoon. The active ingredient in the Ananda investigational new drug, ATL5, is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml od CBD per capsule). The novel formulation is based on the principle that a water-free mixture of some concentrated inactive ingredients (excipients) self-assemble spontaneously into liquid nanodomains that contain the active component CBD. ATL5 Softgel Capsules will be manufactured by Baxco Pharmaceutical Inc., (California, USA) under cGMP conditions.
Trial: NCT06554600
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 160mg bid PO（d0-d20）
Trial: NCT06554600
Drug: Polatuzumab Vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin on Day 2 of each cycle.
Trial: NCT06554600
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 70 mg/m2 Bendamustine on Days 2 and 3 of each cycle.
Trial: NCT06554600
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab on Day 1 of each cycle.
Trial: NCT05985707
Drug: KN026
RxNorm normalized name: ANTI-HER2 BSAB KN026
DrugBank: Anbenitamab (DB18411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes.
Trial: NCT05985707
Drug: KN046
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: KN046 is a novel bispecific antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
Trial: NCT05363384
Drug: CT-L01
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet, single dose, oral administration
Trial: NCT05363384
Drug: Alogliptin Benzoate 25 mg
RxNorm normalized name: Alogliptin Benzoate 25 MG Oral Tablet
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin Benzoate 25 mg, oral administration
Trial: NCT05363384
Drug: Metformin HCl XR 1,000 mg
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin HCl XR 1,000 mg, oral administration
Trial: NCT05823623
Drug: Inetetamab
RxNorm normalized name: Inetetamab
DrugBank: Inetetamab (DB17457)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
Trial: NCT05823623
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
Trial: NCT05823623
Drug: Oral Vinorelbine Tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
Trial: NCT03409081
Drug: gilteritinib
RxNorm normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral
Trial: NCT06307249
Drug: Palbociclib 125mg
RxNorm normalized name: PALBOCICLIB 125MG TAB
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib 125mg/day/os over 21 days every 28 days
Trial: NCT06307249
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg/kg every 21 days
Trial: NCT05262413
Drug: QL1706 Plus Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: QL1706 5mg/kg administered intravenously (IV), every 3 weeks, plus Lenvatinib 20 mg or 14mg administered orally, once daily.
Trial: NCT00001040
Drug: Saquinavir
RxNorm normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001040
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001040
Drug: Zalcitabine
RxNorm normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04824703
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Decreasing fraction of inspired oxygen and its effect on mortality and myocardial function~* administered by invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1
Trial: NCT04554459
Drug: Ponatinib 15 MG Oral Tablet
RxNorm normalized name: PONATinib 15 MG Oral Tablet
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
Trial: NCT05040698
Drug: Fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Open label Fostamatinib
Trial: NCT05434494
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam is injected for 30 seconds and the experimental dose will be determined according to the biased coin design up-and-down sequential method.~If loss of consciousness is successful, the dose of the next intravenous dose of the next study subject will be reduced from the previous dose with a probability of 1/19 or the same as the previous dose with a probability of 18/19.
Trial: NCT04884763
Drug: Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Erenumab-aooe (EREN) 140 mg s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
Trial: NCT06312189
Drug: Valbenazine
RxNorm normalized name: Valbenazine
DrugBank: Valbenazine (DB11915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor
Trial: NCT05901467
Drug: kisspeptin 112-121
RxNorm normalized name: Kisspeptin
DrugBank: Kisspeptin (DB19112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One IV bolus of kisspeptin 112-121
Trial: NCT05901467
Drug: GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One IV bolus of gonadotropin-releasing hormone
Trial: NCT04718740
Drug: fluzoparib
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Caffeine, vitamin K, warfarin, omeprazole, and midazolam with or without fluzoparib Group B: Repaglinide and bupropion with or without fluzoparib
Trial: NCT05325229
Drug: Docetaxel for injection (Albumin-bound)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel for injection (Albumin-bound), by intravenous infusion，75 mg/m\^2 or 100 mg/m\^2 once every 3 weeks.
Trial: NCT05325229
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab, by intravenous infusion, 15 mg/kg once every 3 weeks.
Trial: NCT00008801
Drug: hOKT3gamma1 (Ala-ala)
RxNorm normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05065073
Drug: Iodixanol
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iso-osmolar Contrast Media
Trial: NCT05065073
Drug: Iohexol
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-Osmolar Contrast Media